A phase 3, active (warfarin) controlled, double-blind, double-dummy, randomized study for assessing the efficacy and safety of rivaroxaban in patients with non-valvular atrial fibrilation

dc.contributor.advisor	Στεφανίδης, Ιωάννης Λ.	el
dc.creator	Καραγιαννίδης, Ευστράτιος	el
dc.date.accessioned	2017-04-26T09:09:49Z
dc.date.available	2017-04-26T09:09:49Z
dc.date.issued	2015
dc.identifier.other	14320
dc.identifier.uri	http://hdl.handle.net/11615/46172
dc.identifier.uri	http://dx.doi.org/10.26253/heal.uth.4432
dc.language.iso	en	en
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	en
dc.subject.other	Καρδιαγγειακό σύστημα -- Φάρμακα	el
dc.subject.other	Βιοστατιστική	el
dc.title	A phase 3, active (warfarin) controlled, double-blind, double-dummy, randomized study for assessing the efficacy and safety of rivaroxaban in patients with non-valvular atrial fibrilation	en
dc.type	masterThesis	en
heal.recordProvider	Πανεπιστήμιο Θεσσαλίας - Βιβλιοθήκη και Κέντρο Πληροφόρησης	el
heal.academicPublisher	Πανεπιστήμιο Θεσσαλίας. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής.	el
heal.academicPublisherID	uth	en
heal.fullTextAvailability	true	en
dc.rights.accessRights	free	en

Attribution-NonCommercial-NoDerivatives 4.0 International